Biopharmaceutical News and Research

RSS

New drug shows promise in treating a movement disorder associated with Huntington's disease

A new drug has proven beneficial in treating a movement disorder commonly associated with Huntington's disease, according to a recent international study led by UTHealth Houston researcher Erin Furr Stimming, MD, who served as principal investigator on behalf of the KINECT-HD Huntington Study Group.

13 Apr 2022

New study reveals oral opaganib's potent in vitro activity against Omicron

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced study results in which opaganib (ABC294640), a leading oral drug candidate for hospitalized patients with moderate to severe COVID-19, was observed to have potent in vitro efficacy against the Omicron SARS-CoV-2 variant, while maintaining host cell viability.

11 Apr 2022

EMA issues qualification opinion for islet autoantibodies as enrichment biomarkers for T1D prevention trials

Critical Path Institute's Type 1 Diabetes Consortium (T1DC) today announced that the European Medicines Agency has issued a positive qualification opinion for pancreatic islet autoantibodies as enrichment biomarkers for type 1 diabetes (T1D) prevention trials.

5 Apr 2022

ProteoGenix launches new XtenCHOTM Transient CHO Expression System to improve biologics development

ProteoGenix, a contract research organization specialized in biologics discovery and bioproduction, announces the launch of its XtenCHOTM Transient Expression System.

From ProteoGenix 30 Mar 2022

The Future of Tuberculosis; An Interview with the Bill & Melinda Gates Medical Research Institute

We speak to Dr. Alemnew Dagnew from the Bill & Melinda Gates Medical Research Institute, about their tuberculosis vaccine study and the future of tuberculosis.

16 Mar 2022

Zentalis contributes $1 million to SU2C Catalyst program for research into targeted cancer therapeutics

Stand Up To Cancer and Zentalis Pharmaceuticals, Inc. today announced that Zentalis will contribute $1 million to the SU2C Catalyst program to support research that investigates the use of certain small molecule inhibitors for treating a variety of cancer types.

15 Mar 2022

The Nucleic Acid Experts – Certified Twice!

BioEcho Life Sciences receives two important hallmarks for its quality management – DIN EN ISO 9001:2015 and DIN EN ISO 13485:2016.

From BioEcho Life Sciences GmbH 10 Mar 2022

Texas A&M team continues research on the potential cure for Menkes disease

A life-saving cure solution for Menkes Disease, a copper deficiency in young children, is at the center of a licensing agreement by the The Texas A&M University System, through the Intellectual Property and Commercialization office of Texas A&M AgriLife Research, and a California-based biopharmaceutical company, Engrail Therapeutics.

3 Mar 2022

Phase 2/3 study of oral RHB-107 in non-hospitalized COVID-19 patients shows promising results

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced positive top-line results from the Phase 2 part of the Phase 2/3 study of once-daily oral RHB-107 (upamostat) in non-hospitalized symptomatic COVID-19 patients, predominantly conducted in the U.S. (60/61 patients) as well as South Africa.

1 Mar 2022

Single Use Support brings cell & gene therapy expert Katy Spink on board

Katherine (Katy) Spink has become a member of Single Use Support’s Board of Directors. Her many years of expertise in cell & gene therapy consulting will enrich the companies’ focus on innovating solutions for advanced therapies.

From Single Use Support GmbH 25 Feb 2022

Codiak's publication highlights the ability of exoASO-STAT6 to selectively target tumor-associated macrophages

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced the online publication of a new manuscript, Exosome mediated genetic reprogramming of tumor associated macrophages by exoASO-STAT6 leads to potent monotherapy anti-tumor efficacy, in the American Association for the Advancement of Science's journal, Science Advances.

18 Feb 2022

Integrity Bio and LakePharma Become Curia

Companies Unite Under One Brand to Provide Seamless, Comprehensive Biologics Discovery, Development and Manufacturing Solutions

From Curia Global, Inc. 15 Feb 2022

NIAID's new pandemic preparedness efforts aim to characterize prototype and priority pathogens

As the global COVID-19 pandemic continues into its third year, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is focusing on preparing for a range of other viral threats that could cause a public health emergency.

2 Feb 2022

Aceto consolidates acquisition of six manufacturers, strengthening its unique hybrid model that provides major supply chain benefits to customers

Aceto, a leading global provider of specialty materials for life sciences and advanced technology end markets, today reported it has consolidated and integrated its six manufacturing-related acquisitions to achieve a hybrid manufacturing/distribution model providing key benefits to its customers in high-growth end markets including pharmaceuticals, biopharmaceuticals, vaccines, nutraceuticals, agriculture, cosmetics and specialty chemicals.

27 Jan 2022

New production method developed to freeze-dry COVID-19 vaccines

UMass Lowell scientists are developing a production method to freeze-dry COVID-19 vaccines activated by messenger-RNA so they can be transported and stored at room temperature.

21 Jan 2022

Eikonoklastes completes a license to add novel gene therapy for treating neurodegenerative diseases

Eikonoklastes Therapeutics, a preclinical stage biopharmaceutical company, today announced it has completed a license with the University of California San Diego to add a novel gene therapy for the treatment of neurodegenerative diseases.

20 Jan 2022

Porter Alliance for Innovative Medicines aims to close the gap between scientific research and clinical care

Stanford University and Deerfield Management, a health care investment firm, have collaborated to create Porter Alliance for Innovative Medicines to accelerate translational research into clinical therapeutics.

19 Jan 2022

PhoreMost expands into new facility at Unity Campus, Cambridge, UK

PhoreMost Ltd today announced it has relocated its headquarters to Unity Campus, a high-specification technology and innovation park.

From PhoreMost 18 Jan 2022

Malvern Panalytical expands pharmaceutical drug development solutions through the acquisition of Creoptix

Malvern Panalytical, a company providing advanced analysis and services solutions for the pharma drug product development, as well as services and solutions for other industries, has today announced its acquisition of Creoptix AG, a specialist bioanalysis sensor company.

From Malvern Panalytical 13 Jan 2022

NeoCura and PhoreMost Announce Research Collaboration to Explore Novel Cancer Therapeutics

NeoCura and PhoreMost today announced an oncology drug discovery research collaboration.

From PhoreMost 11 Jan 2022